TACSTD2 and cancer: We report Trop-2 overexpression in 35% of uterine and 57% of the ovarian carcinosarcoma tested by IHC and in two out of four primary carcinosarcoma cell lines available to this study, and we have provided evidence that increased surface expression of Trop-2 is associated with increased cancer cell susceptibility to immune-mediated cytotoxicity in the presence of hRS7.